research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-09. Numbers and descriptions here follow the published literature rather than marketing material.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
The sequence places several glycine and proline residues near the middle, which may influence how the chain folds in solution. The peptide is linear rather than cyclic, and it carries no disulfide bridges. Commercial material is commonly supplied as the acetate salt, although the free base and other counterion forms also appear. Because the term BPC-157 refers to a specific sequence, samples with slight sequence variants are chemically different substances. Published work generally treats the fifteen-residue sequence as the defining structure.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide composed of fifteen amino acids. Its sequence corresponds to part of a protein found in human gastric juice, which is the origin of the "body protection compound" label. In laboratory work the material is treated as a defined research chemical rather than a finished product. Published research has centered on animal models, and the peptide is not an approved medicine in most countries.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Direct human evidence is scarce. One trial in ulcerative colitis delivered the compound by enema and produced limited publicly reported results without a clear benefit. The compound is not an approved medicine in most jurisdictions. In many markets it is sold as a research chemical; in others it falls under prescription or controlled categories. Regulators have not confirmed any claimed medical use, and product labels rarely undergo premarket review.
Most published reports describe experiments in rodents rather than in people. These studies examine outcomes in tendons, ligaments, bone, stomach lining, and intestinal tissue. In rat and mouse models, a frequently reported effect is faster healing or reduced damage. Sample sizes are usually small, and a substantial share of the work originates from a small number of research groups. Independent replication is limited, so how far the findings extend to humans remains an open question.
=== 1997–2016: Valve === In July 1997, Laidlaw joined the video game company Valve while they were developing their first game, the first-person shooter (FPS) Half-Life (1998). He was hired to work on another game, Prospero, but switched when it was cancelled and the Half-Life project expanded. Laidlaw said his contribution was to add "old storytelling tricks" to Valve's ambitious designs. Rather than dictate narrative elements, he worked with the team to improvise ideas and was inspired by their experiments. He contributed to the "visual grammar" of the level design and focused on "doing storytelling with the architecture ... The narrative had to be baked into the corridors." For Half-Life 2 (2004), Valve developed the characterization. Laidlaw created family relationships between the characters, saying it was a "basic dramatic unit everyone understands" that was rarely used in games. He also worked on Half-Life 2: Episode One (2006) and Half-Life 2: Episode Two (2007), plus several canceled Half-Life projects, including Half-Life 2: Episode Three and a virtual reality (VR) game set on a time-travelling ship. Laidlaw said he had intended Episode Three to end the Half-Life 2 story arc, at which point he would "step away from it and leave it to the next generation". In 2012, Laidlaw started a Twitter account to tell a story about the Half-Life 2 character Dr Breen. He described the story as "fan fiction", and wrote: "I personally cannot give the world a Half-Life game.
Outline of the 2026 Iran war Censorship during the 2026 Iran war Impact of the 2026 Iran war on the 2026 FIFA World Cup Misinformation during the 2026 Iran war Operation Project Freedom Alleged Iranian attempts to assassinate Donald Trump Economic impact of the 2026 Iran war Letter from the IRGC to the American people Related events American expansionism under Donald Trump 1979 oil crisis March–May 2025 United States attacks in Yemen 2026 United States intervention in Venezuela Iranian economic crisis List of wars involving Iran
== Further reading == Kundu, Subhas C., ed. (2014). Silk Biomaterials for Tissue Engineering and Regenerative Medicine. Woodhead Publishing Series in Biomaterials. Woodhead Publishing. ISBN 978-0-85709-699-9. Vepari, Charu; Kaplan, David L. (2007). "Silk as a biomaterial". Progress in Polymer Science. 32 (8–9): 991–1007. doi:10.1016/j.progpolymsci.2007.05.013. PMC 2699289. PMID 19543442. Rockwood, Danielle N.; Preda, Rucsanda C.; Yücel, Tuna; Wang, Xiaoqin; Lovett, Michael L.; Kaplan, David L. (2011). "Materials fabrication from Bombyx mori silk fibroin". Nature Protocols. 6 (10): 1612–1631. doi:10.1038/nprot.2011.379. PMC 3808976. PMID 21959241.
Sources: en.wikipedia.org
== Education == Primary schools in the town are: Buttsbury, Brightside, Sunnymede and South Green. There are two secondary comprehensives: Billericay School and Mayflower High School. St John's School in an independent school for children up to the age of 18.
From Zunsser's view that "one cannot practice a profession like a trade" (p.157), he observed that, for instance, "an improvement in the mechanism of an automobile, or of a shoe buckle" — which were "matters of convenience or luxury", and therefore, "[could] be dispensed with easily by those who are forced to do without them" — were in an entirely "different category" from matters concerning "the relief of the sick and the prevention of unnecessary sorrow by the maintenance of individual and public health" which, "as soon as we are in possession of the knowledge of principles or methods which can contribute to these purposes their free utilization becomes a public necessity"; and, from this, he argued that "there is no valid argument in favor of the patenting of a useful method of preserving health, private or public, unless we admit [which Zinsser did not] that medical discoveries in no ethical sense differ from the purely commercial ones" (p.161). In addition to the question of whether it was ethical to patent medical inventions (pharmaceuticals, devices, apparatus, procedures, etc.), or not — in particular, whether "products of scientific research that affect public and individual health, particularly discoveries and inventions of a medical, pharmaceutical, therapeutic, or hygienic nature ...
== Reduced-footprint cement == Growing environmental concerns and the increasing cost of fossil fuels have resulted, in many countries, in a sharp reduction of the resources needed to produce cement, as well as effluents (dust and exhaust gases). Reduced-footprint cement is a cementitious material that meets or exceeds the functional performance capabilities of Portland cement. Various techniques are under development. One is geopolymer cement, which incorporates recycled materials, thereby reducing consumption of raw materials, water, and energy. Another approach is to reduce or eliminate the production and release of damaging pollutants and greenhouse gasses, particularly CO2. Recycling old cement in electric arc furnaces is another approach. A team at the University of Edinburgh has developed the 'DUPE' process based on the microbial activity of Sporosarcina pasteurii, a bacterium precipitating calcium carbonate, which, when mixed with sand and urine, can produce mortar blocks with a compressive strength 70% of that of concrete.
A bronchoscopic transbronchial cryobiopsy, in which a camera is introduced into the airways followed by rapid freezing of an area of lung tissue prior to biopsy is associated with a lower complication rate and a much lower mortality rate compared to VATS or surgical biopsy with near comparable diagnostic accuracy. There are four types of histopathologic patterns seen in ILD: usual interstitial pneumonia, non-specific interstitial pneumonia, organizing pneumonia, and diffuse alveolar damage. There is significant overlap of the histopathological and radiologic features of each ILD type making diagnosis challenging; even with lung biopsy, 15% of cases of ILD cannot be classified.
Sources: en.wikipedia.org
9 September South Vietnamese officials reported that nearly 5,000 South Vietnamese civilians have been killed by PAVN/VC terror during 1969. Funeral services for Ho Chi Minh were held in Ba Đình Square, Hanoi attended by more than 250,000 mourners. Foreign dignitaries in attendance included Alexei Kosygin, Premier of the Soviet Union, Li Xiannian, Vice Premier of China, Gustáv Husák, General Secretary of the Communist Party of Czechoslovakia, Ignacy Loga-Sowiński, Deputy Premier of Poland, Ion Gheorghe Maurer, Prime Minister of Romania, Sihanouk and Souvanna Phouma.
=== Role in cardiovascular disease === Higher levels of circulating "endothelial progenitor cells" were detected in the bloodstream of patients, predicted better outcomes, and patients experienced fewer repeat heart attacks, though statistical correlations between these outcomes and circulating endothelial progenitor cell numbers were scant in the original research. Endothelial progenitor cells are mobilized after a myocardial infarction, and that they function to restore the lining of blood vessels that are damaged during the heart attack. A number of small phase clinical trials have begun to point to EPCs as a potential treatment for various cardiovascular diseases (CVDs). For instance, the year long "Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction" (TOPCARE-AMI) studied the therapeutic effect of infusing ex-vivo expanded bone marrow EPCs and culture enriched EPCs derived from peripheral blood into 20 patients with acute myocardial infarction (MI). After four months, significant enhancements were found in ventricular ejection fraction, cardiac geometry, coronary blood flow reserve, and myocardial viability (Shantsila, Watson, & Lip). A similar study looked at the therapeutic effects of EPCs on leg ischemia caused by severe peripheral artery disease. The study injected a sample of EPC rich blood into the gastrocnemius muscles of 25 patients. After 24 weeks an increased number of collateral vessels and improved recovery in blood perfusion was observed. Rest pain and pain-free walking were also noted to have improved
== Epidemiology == The condition affects adults more frequently than children and males more frequently than females. Most cases occur between the ages of 40 and 60. Polyarteritis nodosa is more common in people with hepatitis B infection.
== External links == US Environmental Protection Agency info on IAQ[link removed] Best Practices for Indoor Air Quality when Remodeling Your Home, US EPA Addressing Indoor Environmental Concerns During Remodeling, US EPA Renovation and Repair, Part of Indoor Air Quality Design Tools for Schools, US EPA The 9 Foundations of a Healthy Building, Harvard T.H. Chan School of Public Health
=== Attitudes about groundwater contamination before 1978 === Groundwater has been a historically important source of water for public water systems, privately owned wells, and agricultural systems for generations. It had been commonly believed that as water traveled through soil, it was stripped of impurities before it could enter groundwater storages; as a result, there wasn't much general concern about contamination of the subsurface environment. In 1960, organic contaminants, including petroleum hydrocarbons, coal tar derivatives, synthetic detergents, and pesticides, had been noted in an extensive literature survey of groundwater contamination that provided the first indication of NAPLs in the subsurface. By the early 1970s, the technological development of gas chromatography provided a new method to detect groundwater contaminants imperceptible to the human senses. This development lead to the discovery and subsequent analysis of chlorinated solvents, one of the most deleterious forms of NAPL. It became understood that NAPLs are challenging both to detect and to remove from the subsurface. Because NAPLs participate in a biological chain of degradation, they produce intermediate chemicals that create particularly acute dangers for human health.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.